All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Do early clinical data show synergy between mosunetuzumab and polatuzumab vedotin in R/R B-cell NHL?

During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Nilanjan Ghosh, Levine Cancer Institute, Charlotte, US. We asked, Do early clinical data show synergy between mosunetuzumab and polatuzumab vedotin in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL)?

Do early clinical data show synergy between mosunetuzumab and polatuzumab vedotin in R/R B-cell NHL?

In this video, Ghosh discusses the combination of mosunetuzumab and polatuzumab vedotin (conjugate antibody) based on results from a phase I study. He believes there is synergy between the two active agents and that they have the potential to induce durable complete remissions.

 

Share: